Bay 59-8862. Oncolytic

Drugs of the Future

Volumn 26, Issue 6, 2001, Pages 533-544

  Pratesi, G ^a   Laccabue, D ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (TERT BUTOXYCARBONYLAMINO) 2 HYDROXY 5 METHYLHEXANOIC ACID 7,12A BIS(ACETOXY) 13 (BENZOYLOXY) 9 HYDROXY 5,8A,14,14 TETRAMETHYL 2,8 DIOXO,3A,4,7,8,8A,9,10,10A,12,12A,12B,13 DODECAHYDRO 6,13A METHANO 13AH; ANTINEOPLASTIC AGENT; ORTATAXEL; OXETO[2'',3'':5',6']BENZO[1',2':4,5]CYCLODECA[1,2 D] 1,3 DIOXOL 4 YL ESTER; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CYTOTOXICITY; DRUG ELIMINATION; DRUG STRUCTURE; DRUG SYNTHESIS; NUDE MOUSE;

EID: 0034804996     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2001.026.06.620123     Document Type: Article

References (50)

1. 14β-Hydroxy-10-deacetyl-baccatin III, a new taxane from Himalayan yew (Taxus wallichiana Zucc.)
2. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents
3. Taxol stabilizes microtubules in mouse fibroblasts
4. Taxol: An antimitotic agent with new mechanism of action
5. Taxol: The supply issue
6. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol
7. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue
8. The taxoids. Comparative clinical pharmacology and therapeutic potential
9. Isolation of a taxol resistant Chinese hamster ovary cell mutant that has an alteration in alpha tubulin
10. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
11. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes
12. Taxol resistant mutants of Chinese hamster ovary cells: Genetic biochemical and cross resistance studies
13. Taxol: Mechanisms of action and resistance
14. Syntheses and structure-activity relationships of taxoids derived from 14β-hydroxy-10-deacetylbaccatin III
15. Anti-proliferative activity of a new class of taxanes (14β-hydroxy-10 -deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells
16. MDA435/LCC6 and MDA435/LCC6MDR1: Ascites models of human breast cancer
17. IDN-5109: A novel, orally active, semisynthetic taxane which modulates P-glycoprotein and overcomes P-glycoprotein mediated multidrug resistance in human colon and breast carcinomas in vitro and in vivo
18. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes
19. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes
20. In vitro and in vivo activity of the new taxane IDN5109 on hormone-resistant prostate cancer cells
21. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts
22. IDN5109, a taxane with oral bioavailability and potent antitumor activity
23. IDN5109, a novel taxane with oral activity against P-glycoprotein resistant tumors
24. IDN5109: An orally available paclitaxel analog active on human renal carcinoma xenografts
25. Paclitaxel (Taxol) mechanisms of resistance
26. Interaction of docetaxel ("Taxotere") with human P-glycoprotein
27. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
28. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A
29. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
30. Oral efficacy and bioavailability of a novel taxane
31. CNS drug design based on principles of blood-brain barrier transport
32. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability
33. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs
34. A novel taxane active against an orthotopically growing human glioma xenograft
35. High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma
36. Differences in the distribution of the novel taxane derivative IDN5109 and of paclitaxel in mice
37. Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies
38. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, given every three weeks in patients with advanced malignancies
39. Phase I and pharmacokinetic study of RPR116258A, a novel taxane derivative, administered intravenously over 1 hour every 3 weeks
40. Phase I and pharmacokinetics (PK) study of RPR 116258A given as 1-hour infusion in patients (pts) with advanced solid tumors
41. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol
42. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol)
43. The coral-derived natural products eleutherobin and sarcodictyins A and B: Effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site
44. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents
45. Epothilones and related structures - A new class of microtubule inhibitors with potent in vivo antitumor activity
46. A phase I clinical and pharmacokinetic study of EP0906 (epothilone B), given every three weeks, to patients with advanced solid tumours
47. Preclinical pharmacology of the epothilone B analog BMS-247550 - An epothilone analog possessing potent activity against paclitaxel sensitive and resistant human tumors
48. Phase I and pharmacology study of the epothilone B analog BMS-247550 in patients with advanced cancer